Teva Reports Full Year 2015 and Fourth Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following Slight 4Q EPS Miss
February 12, 2016 7:33 AM ESTMizuho Securities reiterated a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $78.00 (from $79.00), following the company's 4Q earnings report. Teva reported a modest beat on revenues of $4.88B relative to consensus estimates of $4.84B, but missed bottom-line by a... More
Teva Pharma (TEVA) Misses Q4 EPS by 1c
February 11, 2016 7:04 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $1.28, $0.01 worse than the analyst estimate of $1.29. Revenue for the quarter came in at $4.88 billion versus the consensus estimate of $4.83 billion.
Non-GAAP EPS adjusted to exclude Dec 15 equity offerings was $1.32.
GUIDANCE:
Teva Pharma sees Q1 2016 EPS of $1.32-$1.36, versus the consensus of $1.21. Teva Pharma sees Q1 2016 revenue of $4.7-4.9 billion, versus the consensus of $4.92 billion.
"2015... More
